XNASIMNM
Market cap585mUSD
Jan 14, Last price
9.38USD
1D
-6.57%
1Q
-23.99%
IPO
-22.48%
Name
Immunome Inc
Chart & Performance
P/E
—
P/S
41.77
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
35.22%
Rev. gr., 5y
%
Revenues
14m
Net income
-107m
L+184.72%
CFO
-8m
L-73.62%
Earnings
Mar 26, 2025
Profile
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 14,018 | |||||
Cost of revenue | 123,384 | 37,532 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (109,366) | (37,532) | ||||
NOPBT Margin | ||||||
Operating Taxes | 617 | |||||
Tax Rate | ||||||
NOPAT | (109,366) | (38,149) | ||||
Net income | (106,806) 184.72% | (37,513) 53.31% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 34 | 32 | ||||
BB yield | -0.02% | -0.12% | ||||
| Debt | ||||||
Debt current | 310 | 293 | ||||
Long-term debt | 2,990 | 355 | ||||
Deferred revenue | 5,489 | |||||
Other long-term liabilities | ||||||
Net debt | (134,942) | (19,775) | ||||
| Cash flow | ||||||
Cash from operating activities | (7,568) | (28,690) | ||||
CAPEX | (831) | (248) | ||||
Cash from investing activities | (30,484) | (248) | ||||
Cash from financing activities | 116,408 | 32 | ||||
FCF | (112,038) | (38,259) | ||||
| Balance | ||||||
Cash | 138,142 | 20,323 | ||||
Long term investments | 100 | 100 | ||||
Excess cash | 137,541 | 20,423 | ||||
Stockholders' equity | (222,781) | (116,000) | ||||
Invested Capital | 349,802 | 133,008 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 19,844 | 12,127 | ||||
Price | 10.70 384.16% | 2.21 -82.95% | ||||
Market cap | 212,327 692.27% | 26,800 -82.08% | ||||
EV | 77,385 | 7,025 | ||||
EBITDA | (108,638) | (36,901) | ||||
EV/EBITDA | ||||||
Interest | 5 | |||||
Interest/NOPBT | ||||||